{"id":"nifedipine-cr-tablets-adalat","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Headache"},{"rate":"5-15","effect":"Flushing"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Peripheral edema"},{"rate":"2-5","effect":"Palpitations"},{"rate":"2-5","effect":"Fatigue"},{"rate":"2-5","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nifedipine selectively blocks L-type calcium channels in the cell membrane, preventing calcium-dependent contraction of vascular smooth muscle. This leads to peripheral vasodilation, reduced peripheral vascular resistance, and decreased blood pressure. The drug also has mild negative inotropic effects on the heart and can reduce heart rate, contributing to its antihypertensive and antianginal effects.","oneSentence":"Nifedipine is a calcium channel blocker that inhibits calcium influx into vascular smooth muscle and cardiac cells, causing vasodilation and reduced blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:35:01.675Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Angina pectoris (chronic stable angina)"}]},"trialDetails":[{"nctId":"NCT00768560","phase":"PHASE2","title":"Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-01","conditions":"Hypertension","enrollment":35},{"nctId":"NCT02357615","phase":"PHASE4","title":"Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure","status":"UNKNOWN","sponsor":"Shanghai Shyndec Pharmaceutical Co., Ltd.","startDate":"2014-12","conditions":"Essential Hypertension","enrollment":244},{"nctId":"NCT02031861","phase":"PHASE4","title":"Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension","status":"COMPLETED","sponsor":"Shanghai Shyndec Pharmaceutical Co., Ltd.","startDate":"2014-02","conditions":"Essential Hypertension","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"nifedipine CR tablets (Adalat)","genericName":"nifedipine CR tablets (Adalat)","companyName":"Shanghai Shyndec Pharmaceutical Co., Ltd.","companyId":"shanghai-shyndec-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nifedipine is a calcium channel blocker that inhibits calcium influx into vascular smooth muscle and cardiac cells, causing vasodilation and reduced blood pressure. Used for Hypertension, Angina pectoris (chronic stable angina).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}